Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7M3JN
|
|||
| Drug Name |
Disufenton
|
|||
| Synonyms |
168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | |
| Company |
Oblato
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H15NO7S2
|
|||
| Canonical SMILES |
CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-]
|
|||
| InChI |
1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)
|
|||
| InChIKey |
OVTCHWSLKGENKP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 168021-77-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular sulfatase Sulf-2 (SULF2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04388475) Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.